Expand INKT Menu
INKT MENU

INKT Latest Press Releases

-- April 17, 2026 --

MiNK Therapeutics Reports Phase II Data on Immune Reprogramming and Durable Survival in PD-1 Refractory Gastroesophageal Cancer Globe Newswire 3:00 PM

-- April 3, 2026 --

MiNK Therapeutics and Memorial Sloan Kettering to Present Phase II Study of agenT-797 Combination in PD-1 Refractory Gastroesophageal Cancer at AACR 2026 Globe Newswire 7:30 AM

-- April 2, 2026 --

MiNK Therapeutics to Present New Data at ASGCT 2026 Highlighting Context-Dependent Activity of iNKT Cell Therapy Globe Newswire 7:30 AM

-- April 1, 2026 --

MiNK Therapeutics Announces Abstract Acceptance for Presentation at the American Thoracic Society (ATS) 2026 International Conference Globe Newswire 7:30 AM

-- March 31, 2026 --

MiNK Therapeutics Reports Q4 and Full Year 2025 Results; Phase 2 Programs Advance with Impactful Non-Dilutive Momentum Globe Newswire 7:30 AM

-- March 17, 2026 --

MiNK Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Highlight Platform Expansion Across iNKT Cell Therapy Programs Globe Newswire 7:30 AM

-- March 10, 2026 --

MiNK Therapeutics Announces Collaboration with C-Further to Advance PRAME-Targeted iNKT Cell Therapy for Pediatric Cancers Globe Newswire 5:30 AM
C-Further Unveils First Therapeutic Programmes Dedicated to Paediatric Oncology Business Wire 5:00 AM

-- February 3, 2026 --

MiNK Therapeutics Presents New Data of allo-iNKT Cell Therapy as a Potential Disease-Modifying Approach in Idiopathic Pulmonary Fibrosis at Keystone Symposia Globe Newswire 9:30 PM

-- January 8, 2026 --

MiNK Therapeutics and University of Wisconsin-Madison Announce Phase 1 Clinical Trial of Allo-iNKT Cell Therapy (AgenT-797) to Evaluate Prevention of Graft-Versus-Host Disease Globe Newswire 12:00 PM
Market Data Delayed 15 Minutes